Related Experiment Videos
Antitumor activity of a new antitumor antibiotic, sporamycin
Abstract:
Sporamycin is an antitumor antibiotic isolated from the culture filtrate of Streptosporangium strain No. PO-357. Hydrolysate of the antibiotic showed at least 12 kinds of amino acid, and the molecular weight was calculated approximately as 8,500 approximately 9,000. Antitumor activities of Sporamycin were examined on murine tumors according to different schedules of treatment. After nine daily doses of the antibiotic had been given to dd mice bearing Ehrlich ascites carcinoma, significant increase of lifespan was observed at doses of 5.0 approximately 1.3 mg/kg. A marked decrease in tumor size of sarcoma-180 transplanted subcutaneously was observed when the mice were treated by daily or single injection of Sporamycin. Against leukemia P-388 and L-1210 inoculated intraperitoneally into CDF1 mice, the antibiotic increased lifespan of leukemic mice. The antibiotic also inhibited significantly the growth of human tumor cells in vitro.
Insights
Sporamycin, an antitumor antibiotic, demonstrated significant efficacy against various murine tumors, including Ehrlich ascites carcinoma and sarcoma-180. It also showed promise in treating leukemia and inhibiting human tumor cell growth in vitro.
Area of Science:
- Microbiology
- Pharmacology
- Oncology
Background:
- Sporamycin is an antitumor antibiotic derived from Streptosporangium strain No. PO-357.
- Its hydrolysate contains at least 12 amino acids, with an approximate molecular weight of 8,500-9,000 Da.
Purpose of the Study:
- To evaluate the antitumor activities of Sporamycin against various murine tumor models.
- To assess the efficacy of Sporamycin under different treatment schedules.
Main Methods:
- Antitumor activity was tested on dd mice with Ehrlich ascites carcinoma and subcutaneously transplanted sarcoma-180.
- Efficacy against leukemia P-388 and L-1210 in CDF1 mice was assessed.
- In vitro studies evaluated Sporamycin's effect on human tumor cell growth.
Main Results:
- Significant lifespan increase in mice with Ehrlich ascites carcinoma at doses of 5.0-1.3 mg/kg after nine daily doses.
- Marked reduction in tumor size for sarcoma-180 with daily or single Sporamycin injections.
- Increased lifespan in leukemic mice (P-388 and L-1210) and significant inhibition of human tumor cell growth in vitro.
Conclusions:
- Sporamycin exhibits broad-spectrum antitumor activity in preclinical models.
- The antibiotic demonstrates potential as a therapeutic agent for various cancers, warranting further investigation.